SCHEMBL6992504

SCHEMBL6992504

CCOC(=O)c1c(Nc2ccccc2N)sc2cc(C)ccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
CDC25B P30305 4/20 0.45
CISD2 Q8N5K1 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 6/20 0.41
HSD17B10 Q99714 3/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 6/20 0.41
HPGD P15428 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
ALOX15 P16050 1/20 0.41
GRM6 O15303 3/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6994066 0.89 SMN1; SMN2 (0.54) SMN1; SMN2CDC25BTSHRMAPK1ALDH1A1
SCHEMBL6995771 0.89 SMN1; SMN2 (0.50) SMN1; SMN2CDC25BTSHRMAPK1ALDH1A1
SCHEMBL6998866 0.87 CISD2 (0.45) SMN1; SMN2CDC25BCISD2TSHRMAPK1
SCHEMBL6996750 0.87 SMN1; SMN2 (0.45) SMN1; SMN2CDC25BCISD2TSHRMAPK1
SCHEMBL6995665 0.86 MAPT (0.41) SMN1; SMN2CISD2TSHRMAPK1ALDH1A1
SCHEMBL6990197 0.83 ALDH1A1 (0.43) SMN1; SMN2MAPK1ALDH1A1MAPTHPGD
SCHEMBL6997282 0.83 SMN1; SMN2 (0.51) SMN1; SMN2CDC25BTSHRMAPK1ALDH1A1
SCHEMBL6993052 0.81 LMNA (0.41) SMN1; SMN2CDC25BCISD2MAPK1ALDH1A1
SCHEMBL6999000 0.79 IDO1 (0.44) SMN1; SMN2CDC25BTSHRMAPK1ALDH1A1
SCHEMBL6997271 0.79 MAPT (0.44) SMN1; SMN2CDC25BTSHRMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1016664-B1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2003-07-02 EP disclosed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT SMN1; SMN2 1349/4885CDC25B 240/4885CISD2 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.